- Home
- MGTX vs PRTA Comparison
MGTX vs PRTA Comparison
Compare MGTX & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGTX | PRTA |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 665.7M | 538.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MGTX | PRTA |
|---|---|---|
| Price | $7.74 | $9.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $23.83 | $18.86 |
| AVG Volume (30 Days) | 422.1K | ★ 511.6K |
| Earning Date | 03-12-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,417,000.00 | $11,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $567.62 | $1,183.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 96.83 | N/A |
| 52 Week Low | $4.55 | $4.32 |
| 52 Week High | $9.73 | $16.67 |
Technical Indicators
Market Signals| Indicator | MGTX | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 42.51 |
| Support Level | $7.72 | $8.65 |
| Resistance Level | $8.17 | $10.53 |
| Average True Range (ATR) | 0.38 | 0.48 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 57.62 | 21.81 |
Price Performance
Historical ComparisonAbout MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.